我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

Need for Artificial Intelligence in Pharmaceutical Industry and its Limitations

Varun Pareek, Lokendra Sharma, Sushil Kumar

AI is often being touted as the means to bring about the fourth Industrial Revolution and its role in almost all sectors of our society is almost certain. This brings about an urgent need for evaluating benefits and limitations of AI and machine learning across various sectors. Pharmaceutical industry has pioneered in embracing the use of AI in all of its core areas but the success as of yet seems very limited. The major advantage of AI is that it reduces the time that is needed for drug development and, in turn, it reduces the costs that are associated with drug development, enhances the returns on investment and may even cause a decrease in cost for the end user along with improved drug safety. So in this article we will review the scope and limitations of AI in the pharmaceutical industry.